Fast payoff: A July 9, 2026 PLOS review shows introducing a non-donated ivermectin/albendazole fixed-dose combination (FDC) will face major supply and financing barriers in the countries with highest soil-transmitted helminth (STH) burden. This post shows how to run a rigorous qualitative analysis of NTD funding using AI-enabled workflows to turn the paper’s findings (35 sources reviewed; EMA positive opinion; Ghana licensed late 2025) into policy-ready recommendations and procurement scenarios. Read the original study at PLOS Neglected Tropical Diseases, then use an AI research platform like Evidano to speed coding, compare segments (LIC/LMIC/UMIC), and produce stakeholder-ready syntheses.
Key Takeaways
Introducing a non-donated ivermectin/albendazole fixed-dose combination (FDC) is primarily a financing and procurement challenge in countries with the highest soil-transmitted helminth burden, not solely a clinical issue. The July 9, 2026 PLOS review synthesizing 35 sources finds weak facility-level availability where STH burden is highest, heavy reliance on donations and out-of-pocket spending in LICs/LMICs, and no pooled global financing for NTD medicines.
- 35 sources reviewed in the PLOS review; some low-income countries show 0% facility-level sustained availability of core essential medicines (SARA data).
- About ~1.5 billion people are infected with STH, developers invested around $15 million over a decade in the FDC, and Ghana licensed the FDC in late 2025 (PLOS review).
- Donation scales cited: GSK >12 billion albendazole tablets donated historically; J&J ~2.4 billion mebendazole; Merck/Mectizan >14 billion ivermectin tablets shipped since 1987.
Fast take, why this matters for researchers and policy teams
The PLOS review (published 9 July 2026) finds essential medicine availability is weakest where STH burden is highest, low-income and lower-middle-income countries rely heavily on donations and out-of-pocket spending, and no pooled global financing exists for NTD medicines, which together make a non-donated FDC both a programmatic opportunity and a financing risk.
- 35 sources reviewed; SARA data show some LICs with 0% facility-level sustained availability of core essential medicines.
- Global figures reported in the review: ~1.5 billion people infected with STH; developers invested about $15 million over a decade; EMA gave a positive scientific opinion; Ghana licensed the FDC late 2025.
- Donation scale examples from the review: GSK >12 billion albendazole tablets donated historically; J&J ~2.4 billion mebendazole; Merck/Mectizan >14 billion ivermectin tablets shipped since 1987.
Findings snapshot
| Metric | Value | Source / Note |
|---|---|---|
| Publication date | 9 July 2026 | PLOS Neglected Tropical Diseases |
| Sources reviewed | 35 | Structured review + expert consultation (PLOS paper) |
| Estimated people with STH | ~1.5 billion | PLOS review (Introduction) |
| Development investment (approx.) | $15 million | Decade-long development of FDC (PLOS review) |
| Ghana regulatory status | Licensed late 2025 | PLOS review |
| Examples of donation scale | GSK 12B albendazole; J&J 2.4B mebendazole; Merck 14B ivermectin | PLOS review, donation program summaries |
| Public health spending; Africa (approx.) | 7.3% of budgets | PLOS review (WHO/World Bank figures) |
What the study actually did
The study combined a structured literature review, WHO SARA facility data, World Bank health expenditure indicators, and expert consultation to synthesize barriers and opportunities for FDC supply and financing.
- Framework used: three determinants of sustainable access, facility-level availability, health financing patterns, and donation models.
- Data tools used included SARA for facility availability and World Bank WDI for financing, triangulated with policy reports and program documents.
- Limitations noted: SARA coverage varies by country and year, and some countries lack recent facility-level data.
So what, implications for researchers, donors, and UX/ops teams
For qualitative researchers & evaluators
Qualitative researchers and evaluators should surface how financing narratives differ across ministries, donors, manufacturers, and community health workers.
Primary task: surface how financing narratives differ across stakeholders (ministries, donors, manufacturers, community health workers).
Use cross-segment comparisons (LIC vs LMIC vs UMIC) and code co-occurrence to show where procurement barriers cluster, such as budget cycles, data gaps, and procurement capacity.
Deliverable: a short policy memo with evidence-backed options, for example pooled procurement, tiered pricing, and primary health care integration.
For policy & procurement teams
Policy and procurement teams should translate facility-level availability gaps into procurement scenarios and cost implications for adopting a purchased FDC versus continuing monotherapy donations.
Translate facility-level availability gaps into procurement scenarios and cost implications for adopting FDC vs continuing monotherapy donations.
Model operational cost changes if mass drug administrations shift from donated drugs to purchased FDC, including MDA operational cost estimates (around US$1+ per person) versus targeted clinic-based delivery.
Decision-ready outputs include a prioritized country list by STH burden and procurement readiness, and financing levers to test.
For UX / program ops teams running field interviews
UX and program operations teams should design interview guides that surface technical and political-economic constraints and segment respondent groups for consistent synthesis.
Design interview guides to surface both technical (supply chain issues) and political-economic constraints, such as budget timing and donor agreements.
Segment respondent groups into national, subnational, and frontline actors and use codebooks mapped to the study’s three determinants for consistent cross-site synthesis.
Do more, faster with Evidano, mapping features to the use case
Overview of Evidano
Evidano is an AI-powered qualitative data analysis platform that ingests, harmonizes, and helps analyze mixed qualitative and quantitative documents for reproducible syntheses.
Evidano is an AI-powered qualitative data analysis platform that ingests, harmonizes, and helps analyze mixed qualitative and quantitative documents for reproducible syntheses.
Ingest & harmonize mixed documents
Evidano ingests and harmonizes mixed documents including peer-reviewed papers, gray reports, policy briefs, and datasets so teams can code by document type and date.
Problem: qualitative evidence spans peer-reviewed papers, gray reports, policy briefs, and datasets (SARA, WDI).
Evidano ingests PDFs, Word docs, and spreadsheets, extracts key passages, and links to source metadata so you can code by document type and date.
Thematic, frequency, and cross-segment analysis
Evidano runs automated thematic extraction, frequency counts, and cross-segment contrasts to compare themes across income groups quickly and reproducibly.
Problem: comparing themes across income groups (LIC/LMIC/UMIC) is time-consuming and error-prone.
Evidano runs automated thematic extraction, frequency counts, and cross-segment contrasts (for example, how often procurement barriers co-occur with 'out-of-pocket' in LICs).
Reproducible codebook & AI-assisted coding
Evidano supports a hierarchical codebook, auto-suggests codes, and provides AI-pre-coded excerpts to speed reviewer reconciliation and increase trust in syntheses.
Problem: inconsistent coding across analysts reduces trust in syntheses.
Evidano allows import or creation of a hierarchical codebook, auto-suggests codes, and surfaces AI-pre-coded excerpts for faster consensus.
Stakeholder-ready visualizations & outputs
Evidano generates exportable visualizations and clickable quotes for memos and slide decks to make qualitative nuance actionable for stakeholders.
Problem: turning qualitative nuance into policy briefs and procurement scenarios is manual.
Evidano generates exportable visualizations (co-occurrence networks, hierarchical code maps) and clickable quotes for memos and slide decks.
Security & ethics
Evidano uses end-to-end encryption and does not use client data to train third-party large language models, and teams should follow local consent and data-protection rules for interview data.
Evidano uses end-to-end encryption and does not use client data to train third-party LLMs.
Note: analyses are research-focused and non-diagnostic; follow local consent and data-protection rules for interview data.
Checklist: 7-step workflow to reproduce this analysis in 2 weeks
Step 1: Collect materials, download the PLOS review and related donation program reports, SARA extracts, and World Bank WDI tables.
Step 2: Ingest into Evidano, upload documents and spreadsheets, and tag by country and year.
Step 3: Import or create a codebook reflecting the three determinants: availability, financing, and donation models.
Step 4: Run AI-assisted coding and review suggested excerpts, then reconcile differences with one reviewer pass.
Step 5: Run cross-segment analyses (LIC vs LMIC vs UMIC) and generate co-occurrence networks to identify clustered barriers.
Step 6: Produce two deliverables, a 2-page policy brief with the top 3 financing options and a slide pack with visuals.
Step 7: Share an interactive report with stakeholders for rapid feedback and iterate using version-controlled exports.
Conclusion, next moves
The PLOS review (9 July 2026) shows that introducing a non-donated ivermectin/albendazole FDC is as much a financing and procurement problem as a clinical one, and researchers and policy teams can accelerate decision-making by running a focused qualitative analysis that ties SARA and WDI data to stakeholder narratives.
Start by reproducing the paper’s thematic map, then use cross-segment contrasts to produce country prioritization and financing options. To run this workflow faster and reproducibly, Try Evidano for free, ingest the PLOS paper and associated datasets, auto-code, compare segments, and export policy-ready briefs in days instead of months.
FAQ: NTD funding and FDC rollout
What did the PLOS review find about medicine availability and financing?
The PLOS review found that medicine availability is weakest where STH burden is highest and that many LICs/LMICs rely on donations and out-of-pocket spending.
The review synthesizes 35 sources and uses SARA and WDI data to show facility-level availability gaps and financing patterns, noting there is no pooled global financing for NTD medicines.
How many sources and what key dates are reported in the review?
The review synthesized 35 sources and was published on 9 July 2026, and Ghana licensed the FDC in late 2025.
The study also reports that developer investment totaled about $15 million over the decade-long FDC development and cites donation scales from major manufacturers.
What data and methods did the authors use to reach their conclusions?
The authors combined a structured literature review, WHO SARA facility data, World Bank WDI indicators, and expert consultation to synthesize barriers and opportunities.
The methods included triangulation across peer-reviewed and gray literature, facility-level availability assessment with SARA, financing patterns from WDI, and consultations with experts.
What are the main barriers to introducing a non-donated FDC?
The main barriers are facility-level availability gaps, lack of pooled financing, dependence on donations, and procurement and budgetary constraints at national and subnational levels.
These barriers create programmatic opportunities and financing risks, meaning countries may need pooled procurement, tiered pricing, or PHC integration to adopt a purchased FDC.
How can teams reproduce the qualitative analysis quickly?
Teams can reproduce the analysis in about two weeks by collecting the PLOS review, donation reports, SARA and WDI data, and running a structured codebook and AI-assisted coding workflow.
Follow the seven-step checklist: collect materials, ingest into Evidano, create or import a codebook mapped to availability, financing, and donation models, run coding and cross-segment analyses, and produce policy-ready deliverables.